FY2027 Earnings Estimate for MIRM Issued By Leerink Partnrs

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Investment analysts at Leerink Partnrs boosted their FY2027 EPS estimates for shares of Mirum Pharmaceuticals in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn $2.45 per share for the year, up from their prior forecast of $2.22. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

A number of other research analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Wednesday, October 8th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Wednesday. TD Cowen upgraded Mirum Pharmaceuticals to a “strong-buy” rating in a report on Thursday, September 25th. Evercore ISI boosted their target price on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 26th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $83.50.

Mirum Pharmaceuticals Trading Down 1.2%

Shares of Mirum Pharmaceuticals stock opened at $70.09 on Thursday. The firm has a market capitalization of $3.52 billion, a PE ratio of -81.50 and a beta of 0.75. The company’s fifty day moving average price is $73.22 and its two-hundred day moving average price is $58.67. Mirum Pharmaceuticals has a 52-week low of $36.88 and a 52-week high of $78.54. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.13 and a quick ratio of 2.97.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 17.40%. The business’s revenue was up 47.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.30) EPS. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Activity at Mirum Pharmaceuticals

In related news, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $74.40, for a total value of $1,264,800.00. Following the completion of the sale, the director owned 15,703 shares in the company, valued at $1,168,303.20. This represents a 51.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Eric Bjerkholt sold 9,578 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $76.01, for a total transaction of $728,023.78. Following the completion of the sale, the chief financial officer directly owned 39,945 shares in the company, valued at $3,036,219.45. This represents a 19.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 66,578 shares of company stock worth $4,472,824 in the last quarter. Corporate insiders own 14.36% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. CWM LLC grew its position in Mirum Pharmaceuticals by 259.4% in the first quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares in the last quarter. MCF Advisors LLC grew its stake in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares in the last quarter. Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter. Quarry LP bought a new stake in Mirum Pharmaceuticals during the first quarter worth $56,000. Finally, Osaic Holdings Inc. raised its position in Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after acquiring an additional 351 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.